This Week in Oncology: Colorectal Cancer Surgery and Immunotherapy Advances

From the New England Journal of Medicine, a trial examined the role of tumor debulking in multiorgan metastatic colorectal cancer. The study enrolled 382 adult patients across 27 hospitals in the Netherlands and one in the UK. Patients receiving tumor debulking followed by chemotherapy showed no overall survival benefit compared with chemotherapy alone, with a median of 30.0 months versus 27.5 months. The addition of debulking significantly increased the rate of serious adverse events, suggesting this approach should not be considered standard care for this population.

Meanwhile, researchers in JAMA reported on a similar topic regarding surgical intervention. This randomized clinical trial found that tumor debulking plus chemotherapy did not improve overall survival in multiorgan metastatic colorectal cancer patients. The authors describe how the addition of debulking significantly increased the rate of serious adverse events, indicating that systemic chemotherapy alone may be preferable for this specific group.

Elsewhere this week, attention turned to immunotherapy options for advanced solid tumors. A study reported in the Journal of clinical oncology evaluated ultra-low-dose nivolumab against standard chemotherapy in patients with advanced solid tumors progressing after prior therapy. The study reported improved overall survival and fewer severe adverse events with the immunotherapy regimen compared to chemotherapy. However, results are preliminary as the data were presented in abstract form with limited follow-up details.

In Gut, researchers described findings on incidental findings in trauma whole-body CT scans. This systematic review and meta-analysis synthesized data on incidental findings from trauma whole-body CT scans. The authors found that incidental findings requiring any intervention occurred in 29.8% of patients, with very low certainty. The review highlights non-uniform grading criteria and sparse data as key limitations.

A separate study in Lancet looked at recurrent ovarian carcinoma. This randomised, double-blind phase 3 study evaluated pembrolizumab plus paclitaxel versus placebo plus paclitaxel in 643 female participants with recurrent epithelial ovarian cancer. The combination significantly improved progression-free survival and overall survival compared to chemotherapy alone. These findings support the regimen as a treatment option, though safety profiles require careful monitoring.

Finally, The New England journal of medicine published a phase 3 randomized trial evaluating 1360 men with locally advanced prostate cancer across 75 U.K. centers. Transdermal estradiol patches demonstrated noninferiority to luteinizing hormone-releasing hormone agonists for 3-year metastasis-free survival. Clinicians should weigh the reduced hot flashes against increased gynecomastia risk when considering treatment options.